Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

The news will intensify pressure on Pfizer Chief Executive Officer Albert Bourla, who has repeatedly pointed to the drugmaker’s pipeline as an undervalued source of future growth.

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Pfizer just pulled the plug on its daily weight-loss pill, danuglipron, after a clinical trial flagged a potential ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

Top executives including Apple's Tim Cook, Qualcomm's Cristiano Amon, Pfizer's Albert Bourla and Saudi Aramco's Amin Nasser are attending the two-day conference. News earlier reported that plans were ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer Inc. has said it will discontinue development of its closely watched obesity pill, danuglipron, dealing a severe blow to the company’s ambitions to compete in the rapidly growing weight-loss ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...